Form 8-K Sage Therapeutics, Inc. For: Jan 07

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. PLTR
6. JNJ
7. QQQ
8. LDOS
9. HUM
10. CSCO

Go back to Form 8-K Sage Therapeutics, Inc. For: Jan 07

Sage Therapeutics (SAGE) ~45% Upside Does Not Nearly Reflect Potential Market Opportunity - RBC

January 7, 2019 1:03 PM EST

RBC Capital analyst Brian Abrahams weighed in on Sage Therapeutics (NASDAQ: SAGE) following a Q&A session hosted by management, which the analyst noted offered mostly incremental tidbits, and overall supports their comfort and enthusiasm around efficacy/safety of 217 in PPD and... More

SAGE Therapeutics (SAGE) 'Hits It Out of the Park' with SAGE-217 Data - Cowen

January 7, 2019 11:56 AM EST

Cowen analyst Ritu Baral reiterated an Outperform rating and $207 price target on Sage Therapeutics (NASDAQ: SAGE) after the company reported highly positive top-line data from the Ph3 ROBIN study of SAGE-217 in postpartum depression.

Baral commented, "The trial met primary endpoint with... More

Sage Therapeutics (SAGE) SAGE-217 Ph3 Data 'Very Impressive' - BMO

January 7, 2019 11:52 AM EST

BMO Capital analyst Gary Nachman reiterated an Outperform rating and $203 price target on Sage Therapeutics (NASDAQ: SAGE) after the company reported "very impressive" Ph3 data for SAGE-217 in PPD that demonstrated strong efficacy across the board and an overall good safety... More

Sage Therapeutics (SAGE) PT Raised to $90 at Leerink Partners

January 7, 2019 11:48 AM EST

Leerink Partners analyst Marc Goodman raised the price target on Sage Therapeutics (NASDAQ: SAGE) to $90.00 (from $80.00) while maintaining a Underperform rating.

... More